UK markets closed

BioSenic S.A. (0R55.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0220-0.0002 (-0.90%)
At close: 04:20PM GMT
Full screen
Previous close0.0222
Open0.0220
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0216 - 0.0220
52-week range0.0216 - 0.1890
Volume11,451
Avg. volume12,067
Market cap2,248
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.7670
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress

    PRESS RELEASE Preclinical data in a transgenic mouse model shows beneficial effects on various clinical symptoms analogous to those observed in human systemic sclerosis.Findings may further support future clinical program. Mont-Saint-Guibert, Belgium, 20 March 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, presented the latest data on arsenic trioxide (ATO) for systemic scl

  • Globe Newswire

    BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease

    INSIDE INFORMATION New data builds on earlier findings from a post-hoc Phase 2 analysis that helped reposition BioSenic’s oral arsenic trioxide (OATO) program for pivotal trials.Data to be submitted for peer-reviewed publication. Mont-Saint-Guibert, Belgium, 12 March 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces the publication of an open-access article d

  • GlobeNewswire

    BioSenic S.A. : Information on the total number of voting rights and shares

    PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 29 February 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major